Description

Arixtra (fondaparinux natrium) solution for injections 12.5 mg/ml. 0.6 ml. (7.5 mg.) №10 in syringe

Ingredients:

Each 0.6 ml syringe contains 7.5 mg of fondaparinux natrium as the active ingredient.

Dosage:

The recommended dosage of Arixtra is 2.5 mg once daily administered by subcutaneous injection.

Indications:

Arixtra is indicated for the prevention of venous thromboembolic events in patients undergoing orthopedic surgery.

Contraindications:

Do not use Arixtra in patients with active major bleeding or severe renal impairment (CrCl < 30 mL/min).

Directions:

Administer Arixtra by subcutaneous injection into the abdomen, once daily. Rotate injection sites.

Scientific Evidence:

Fondaparinux, the active ingredient in Arixtra, is a synthetic pentasaccharide that selectively inhibits factor Xa. This mechanism of action prevents the conversion of prothrombin to thrombin, thereby inhibiting the coagulation cascade and reducing the risk of thrombus formation.

Clinical trials have demonstrated the efficacy of fondaparinux in preventing venous thromboembolism in orthopedic surgery patients. A study by Turpie AG et al. showed that fondaparinux was superior to enoxaparin in preventing deep vein thrombosis following hip fracture surgery.

Additional Information:

Arixtra should be used with caution in patients with a history of heparin-induced thrombocytopenia. Monitor platelet counts regularly during treatment.

In conclusion, Arixtra (fondaparinux natrium) solution for injections is a valuable anticoagulant agent with proven efficacy in preventing thromboembolic events. Its selective inhibition of factor Xa makes it a preferred choice in certain patient populations, especially those undergoing orthopedic surgery.